The Chemical Synthesis Facility is one of five contracts used by the Contraceptive Discovery and Development Branch (CDDB) (formerly the Contraception and Reproductive Health [CRH] Branch) to support research on the discovery, optimization and development of male and female contraceptive agents.
This facility provides NICHD-supported researchers and other investigators with research grade and clinical grade Active Pharmaceutical Ingredients (APIs).
The Chemical Synthesis Facility manufactures research grade and clinical grade APIs that are identified as promising agents for male and female contraceptives. The facility can manufacture multikilogram clinical grade API under current Good Manufacturing Practice (cGMP). The research grade APIs are tested in in vitro screening and other studies and in vivo animal studies. The APIs manufactured under cGMP protocol by the facility are used in clinical trials.